1. Introduction
===============

The latest Global cancer statistics 2018 showed that gastric cancer has become the fifth most prevalent cancer and the third leading cause of cancer-related death worldwide.^\[[@R1]\]^ The main reasons for the decline in the incidence and mortality of GC may be attributed to the popularity of gastroscopy and the diversity of treatment methods.^\[[@R2],[@R3]\]^ However, the incidence of GC has been kept in a high level in China, and its 5-year survival rate is only 35.9%, far lower than South Korea\'s 68.9% and Japan\'s 60.3%.^\[[@R4]\]^ Due to the lack of effective screening, the majority of patients are in advanced stage at the initial diagnosis, and their 5-year survival rate is less than 30%, and the prognosis of unresectable AGC patients are more serious.^\[[@R5]\]^

According to the GC NCCN guidelines, radical gastrectomy is the standard treatment method and the chemotherapy, radiotherapy and biological immunotherapy are important adjuvant therapy methods.^\[[@R6]\]^ However, the first-line chemotherapy regimens recommended by the NCCN guidelines for unresectable AGC patients are various without clear indications, and the comparation of relative efficacy.^\[[@R5],[@R7]\]^

Paired meta-analysis has the disadvantage of not being able to integrate all the information of chemotherapy methods from different original studies at the same time. Therefore, it is impossible to compare the pros and cons of different chemotherapy regimens. However, even if there was lacking of head-to-head comparisons, the network meta-analysis can also evaluate the relative effectiveness and rank the interventions among all chemotherapy methods for AGC patients, and provide more evidence-based guidance for clinical practice.^\[[@R8]\]^

The aim of this study is to evaluate the relative efficacy of different adjuvant treatments for AGC patients in the improvement of 1-, 2-, 3-year survival rates, survival time, short-term curative effects and the performance status (PFS) through this network meta-analysis.

2. Methods
==========

2.1. Registration
-----------------

This network meta-analysis protocol according to the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) extension statement.^\[[@R9]\]^ Our protocol has been registered on the international prospective register of systematic review (PROSPERO) network. The registration number was CRD42018111835.

2.2. Ethics and dissemination
-----------------------------

### 2.2.1. Ethics issues

This network meta-analysis is a secondary research which based on some previously published data. Therefore, the ethical approval or informed consent was not required in this meta-analysis.

### 2.2.2. Publication plan

This network meta-analysis will be published in a peer-reviewed journal.

2.3. Inclusion criteria
-----------------------

### 2.3.1. Types of studies

RCTs and non-RCTs will be incorporated in this study without published year, publication status limitations.

### 2.3.2. Types of participants

AGC Patients without age, gender, racial and region limitations, which were diagnosed and classified according to the NCCN guideline^\[[@R6]\]^;

### 2.3.3. Types of interventions

According to different chemotherapy regimens, there are 7 interventions: only fluoropyrimidine, only paclitaxel/docetaxel, fluoropyrimidine (include fluorouracil or capecitabine) with oxaliplatin/cisplatin, paclitaxel/docetaxel with cisplatin/carboplatin, fluorouracil with irinotecan, modified DCF regimen (docetaxel, cisplatin/carboplatin/oxaliplatin, and fluorouracil), ECF or modified ECF regimen (epirubicin, cisplatin/oxaliplatin, and fluorouracil/capecitabine). Based on the different drugs in each intervention group, a more detailed subgroup analysis will be conducted to present the efficacy of different drugs.

### 2.3.4. Type of outcomes

The primary outcomes are 1-, 2-, 3-year survival rates and overall survival. The secondary outcomes are short term efficacy according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST Criteria 1.1).

2.4. Information source
-----------------------

Five databases were searched as followings: PubMed, the Cochrane Library, Web of Science, Clinical Trials and EMBASE. The references of included articles and other relevant studies will be also tracked for additional supplement.

The retrieval keywords as followings: advanced gastric neoplasm, advanced gastric cancer, advanced stomach neoplasm, advanced stomach cancer, and adjuvant chemotherapy.

2.5. Data collection and analysis
---------------------------------

### 2.5.1. Data management

Endnote X7 software will be used for literature managing and records searching. A pilot-test will be conducted to ensure the inter-rater is reliability between the reviewers before the literature selection.

### 2.5.2. Selection process

Two independent researchers will conduct a systematic search on above 5 databases according to the predetermined search strategy. In the case of the above-mentioned screening of documents and the extraction of data, if there is a disagreement, it will be resolved through discussion or assistance to a third reviewer. All the study selection process will be revealed in a flow diagram in accordance with the PRISMA guidelines.^\[[@R10]\]^

### 2.5.3. Data collection process

Two independent researchers extracted data in the same predetermined table through the excel software. Any disagreements will be resolved by a third reviewer. The extraction data items as following: the first author, country, published year, the trial design, sample size, age, gender, regimen of adjuvant treatments, tumor pathological classification, TNM stage, 1-, 2-, 3-year survival rates, short-term effect (CR, PR, SD, PD), the PFS of patients, and some other outcomes of interest.

2.6. Quality of evidence assessment
-----------------------------------

According to Grading of Recommendations Assessment Development and Evaluation (GRADE), the quality of included studies will be assessed by the online guideline development tool (GDT, <http://gdt.guidelinedevelopment.org/>), and divided into 4 levels: high quality, moderate quality, low quality, and very low quality.^\[[@R11]\]^

2.7. Risk of bias individual studies
------------------------------------

The risk of bias individual RCT studies will be evaluated from 7 specific domains (sequence generation, allocation concealment, blinding of participants and personnel, incomplete outcome data, selective reporting, and other bias and risk) on the basis of the Cochrane Handbook version 5.1.0.^\[[@R12]\]^ The methodological quality will be also evaluated as low risk, high risk, or unclear risk of bias in accordance with the criteria of the risk of bias judgment.^\[[@R13]\]^ According to the tool for assessing risk of bias in non-randomized studies of interventions (ROBINS-I),^\[[@R14]\]^ the risk of bias of non-randomized studies which included in this network meta-analysis will be estimated as following: confounding, the selection of participants, intervention classification, bias due to deviations from intended interventions, missing data, the measurement of outcomes, the selection of the result reporting, and overall risk bias. The risk of bias will be divided into five parts as following: low, moderate, serious, critical risk of bias, and no information. All the assessment of risk of bias will be performed and finished by 2 researchers independently, any disagreements will be resolved through a third researcher.

2.8. Geometry of the network
----------------------------

The function of *'forest.netmeta'* of R-3.4.1 (R Foundation for Statistical Computing, Vienna, Austria) will be used to draw network plots to describe and present the geometry of different chemotherapy regimens. The nodes and edges will be used to reveal the head-to-head comparisons among interventions.

2.9. Pairwise meta-analysis
---------------------------

The extracted data of all the included studies will be summarized and presented through Excel 2010. Pairwise meta-analysis will be conducted R-3.4.1 software. The statistical heterogeneity among included studies will be assessed by Higgins *I*^*2*^ statistic (large, if *I*^*2*^\> 50%; medium if 25% \< *I*^*2*^ ≥ 50%; and small if 0 ≤ *I*^*2*^ ≥ 25%).^\[[@R15]\]^ Fixed-effect model analysis will be performed, if there is no evidence showed heterogeneity; Otherwise, random-effect model analysis will be chosen after excluding the sources of heterogeneity.

2.10. Network meta-analysis
---------------------------

The '*netmeta*' version 0.9--8 of R-3.4.1 software will be used to perform a network meta-analysis to synthesize direct and indirect evidence for assessing the therapeutic effect among different adjuvant chemotherapy regimens for AGC patients who have lost the surgery opportunities.^\[[@R16]\]^ Inconsistency between direct and indirect comparisons will be assessed by the node splitting method when a loop connecting three arms existed. The treatment effects of different chemotherapy regimens for AGC patients will be ranked by the *P* scores which based on the point estimates and standard errors of the network assessment.

2.11. Other analyses
--------------------

### 2.11.1. Subgroup and sensitivity analyses

Subgroup analyses, which are designed for age, gender, region and different adjuvant chemotherapy regimens, will be used to find the possible sources on account of a possibility of significant heterogeneity or inconsistency.

### 2.11.2. Publication bias

Egger graph and Begg graph will be drawn by the STATA V.12.0 software to identify whether this meta-analysis will have a publication bias.
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